PROSPECT IIA large multi-center prospective study was designed to assess the ability of intravascular imaging to identify non-obstructive coronary plaque that may cause future adverse events. After successfully treating all flow-limiting lesions in patients with recent myocardial infarction, investigators performed NIRS+IVUS intravascular imaging of all three coronary arteries. Patients were then followed for any adverse events that may have been caused by previously identified untreated non-culprit lesions.
PROSPECT ABSORBA sub-study embedded in the present study. Patients with angiographically, non-obstructive lesions with site-determined IVUS plaque burden were randomized to treatment with a bioresorbable scaffold versus medical therapy alone. These patients underwent repeat angiography and intravascular imaging at 25 months.
The Makoto™ Intravascular Imaging System and its accompanying Dualpro™ IVUS + NIRS catheter, is the only FDA-cleared imaging system indicated for the detection of plaque and patients at higher risk of MACE.
To request more information on how to obtain the Makoto™ system, or to see a demo, CLICK HERE
View the PROSPECT II Study as presented at TCT 2020View TCT Presentation
View the PROSPECT ABSORB Substudy highlights and presentation at TCT 2020VIEW STUDY HIGHLIGHTS View TCT Presentation
View the PROSPECT ABSORB Substudy published in JACCVIEW JACC ABSTRACT
© 2022 Infraredx™, Inc. All Rights Reserved Powered by Bloom Creative